← Back to Screener
Neuphoria Therapeutics Inc. Common Stock (NEUP)
Price$5.03
Favorite Metrics
Price vs S&P 500 (26W)-81.49%
Price vs S&P 500 (4W)-6.02%
Market Capitalization$25.71M
All Metrics
P/CF (Annual)333.09x
Book Value / Share (Quarterly)$5.52
P/TBV (Annual)0.94x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)696.24%
Cash Flow / Share (Quarterly)$-0.44
Price vs S&P 500 (YTD)18.80%
Net Profit Margin (TTM)59.50%
EPS (TTM)$-2.12
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-2.12
EPS (Annual)$-0.23
ROI (Annual)-1.94%
Cash / Share (Quarterly)$4.12
ROA (Last FY)-1.29%
Revenue Growth TTM (YoY)-27.00%
EBITD / Share (TTM)$-1.87
Operating Margin (TTM)52.82%
Cash Flow / Share (Annual)$0.04
P/B Ratio0.87x
P/B Ratio (Quarterly)0.70x
Net Income / Employee (Annual)$-0
Net Interest Coverage (TTM)-2.37x
ROA (TTM)-18.38%
EPS Incl Extra (Annual)$-0.23
Current Ratio (Annual)3.56x
Quick Ratio (Quarterly)9.03x
3-Month Avg Trading Volume0.06M
52-Week Price Return-6.65%
EV / Free Cash Flow (Annual)46.34x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$4.69
P/S Ratio (Annual)1.64x
Asset Turnover (Annual)0.55x
52-Week High$21.40
EPS Excl Extra (Annual)$-0.23
26-Week Price Return-72.74%
Quick Ratio (Annual)3.39x
13-Week Price Return18.07%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.04x
Enterprise Value$3.578
Asset Turnover (TTM)0.64x
Revenue / Employee (Annual)$2
Pretax Margin (Annual)-5.35%
Cash / Share (Annual)$7.18
3-Month Return Std Dev45.90%
Net Income / Employee (TTM)$-1
ROE (Last FY)-1.95%
Net Interest Coverage (Annual)-8.22x
EPS Basic Excl Extra (Annual)$-0.23
Receivables Turnover (TTM)0.76x
EV / Free Cash Flow (TTM)13.82x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.12
Receivables Turnover (Annual)2.60x
ROI (TTM)-25.94%
P/S Ratio (TTM)1.64x
Revenue / Share (Annual)$9.64
Tangible BV / Share (Annual)$7.18
Price vs S&P 500 (52W)-41.75%
Year-to-Date Return22.94%
5-Day Price Return4.38%
EPS Normalized (Annual)$-0.23
ROA (5Y Avg)-36.63%
Net Profit Margin (Annual)-2.36%
Month-to-Date Return17.20%
EBITD / Share (Annual)$0.05
Operating Margin (Annual)-7.21%
P/CF (TTM)32.84x
EPS Basic Excl Extra (TTM)$-2.12
P/TBV (Quarterly)0.83x
P/B Ratio (Annual)0.70x
Pretax Margin (TTM)59.05%
Book Value / Share (Annual)$9.61
Price vs S&P 500 (13W)15.20%
Beta0.62x
P/FCF (Annual)333.09x
Revenue / Share (TTM)$3.31
ROE (TTM)-25.98%
52-Week Low$3.65
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NEUPNeuphoria Therapeutics Inc. Common Stock | 1.64x | -27.00% | — | — | $5.03 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Neuphoria Therapeutics is a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders. Its lead candidate, BNC 210, is an oral selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor in development for acute social anxiety disorder and chronic post-traumatic stress disorder. The company focuses on allosteric ion channel modulators targeting central nervous system disorders with significant unmet medical needs.